News
We send the latest information from SMC Laboratories.
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (Nove…
Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and af…
Preclinical HCC study with positive control, Lenvatinib
We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improv…
Enhance Research with Our Updated Model Lineup
We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offer…
Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH…
Case study: Study published in Biomolecules on the effects of MSC-sEV in skin fibrosis of BLM-SSc model.
We introduce a case study of drug efficacy evaluation of Mesenchymal stem/stromal cell-derived small extracell…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…
The STAM™ mouse: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad S…
Introducing our skin disease model: Imiquimod (IMQ)-induced psoriasis model
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatit…